Similarly, Chen et al. [16] conducted a phase I clinical trial (ChiCTR2200058969) with donor-derived CD7 CAR-T cells and achieved 100% optimal CR in seven patients with R/R T-ALL/LBL. This evidence concerns the gene CD7 and acute lymphoblastic leukemia.